Virax Biolabs Group 

$0.19
0
-$0.01-2.72% Thursday 07:33

Statistics

Day High
0.21
Day Low
0.18
52W High
-
52W Low
-
Volume
170,385
Avg. Volume
-
Mkt Cap
1.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Next
-0.49
-0.16
0.18
0.51
Expected EPS
N/A
Actual EPS
N/A

Financials

-101,016.67%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
12,000Revenue
-12.12MNet Income

Analyst Ratings

$1.00Average Price Target
The highest estimate is 1.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRAX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE is a competitor because it also focuses on developing and commercializing immunotherapies for infectious diseases, similar to Virax Biolabs' focus on viral diagnostics and immune health.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is involved in the development of mRNA vaccines for infectious diseases, competing directly with Virax Biolabs' efforts in viral diagnostics and vaccine-related research.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes in the development of vaccines for infectious diseases, directly challenging Virax Biolabs' market in viral diagnostics and immune response solutions.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio in vaccines and therapeutics for infectious diseases, making it a competitor to Virax Biolabs, especially in the COVID-19 and other viral vaccine spaces.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in the research and development of vaccines, including for viral infections, positioning it as a competitor to Virax Biolabs in the field of infectious disease prevention.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc works on vaccines and therapeutics for infectious diseases, competing with Virax Biolabs in the area of viral diagnostics and vaccine development.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers diagnostics and medical devices for infectious diseases, including viral infections, making it a competitor in the diagnostics space where Virax Biolabs operates.
QuidelOrtho
QDEL
Mkt Cap1.83B
Quidel Corporation specializes in diagnostic solutions for infectious diseases, directly competing with Virax Biolabs in the development of tests and diagnostics for viruses.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific Inc. provides a wide range of analytical instruments and diagnostic tools, including for infectious diseases, competing with Virax Biolabs in the diagnostics market.
Hologic
HOLX
Mkt Cap16.45B
Hologic, Inc. focuses on diagnostics and medical imaging, including for infectious diseases, making it a competitor in the market for viral diagnostics and related technologies that Virax Biolabs targets.

About

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Show more...
CEO
ISIN
KYG9495L1251

Listings

0 Comments

Share your thoughts

FAQ

What is Virax Biolabs Group stock price today?
The current price of VRAX.BOATS is $0.19 USD — it has decreased by -2.72% in the past 24 hours. Watch Virax Biolabs Group stock price performance more closely on the chart.
What is Virax Biolabs Group stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Virax Biolabs Group stocks are traded under the ticker VRAX.BOATS.
What is Virax Biolabs Group market cap?
Today Virax Biolabs Group has the market capitalization of 1.22M
When is the next Virax Biolabs Group earnings date?
Virax Biolabs Group is going to release the next earnings report on June 03, 2026.
What were Virax Biolabs Group earnings last quarter?
VRAX.BOATS earnings for the last quarter are -0.49 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Virax Biolabs Group revenue for the last year?
Virax Biolabs Group revenue for the last year amounts to 12,000 USD.
What is Virax Biolabs Group net income for the last year?
VRAX.BOATS net income for the last year is -12.12M USD.
When did Virax Biolabs Group complete a stock split?
Virax Biolabs Group has not had any recent stock splits.